Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment

Suzanne D Westfall; Michael K Skinner

doi:10.1158/1535-7163.MCT-05-0192

Back

Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment

Journal article

Open access

Peer reviewed

Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment

Suzanne D Westfall and Michael K Skinner

Molecular cancer therapeutics, Vol.4(11), pp.1764-1771

11/2005

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0192

Handle:

https://hdl.handle.net/2376/101995

PMID: 16275998

Files and links (2)

pdf

Inhibition of phosphatidylinositol 3-kinase 465.03 kBDownload View

Open Access

url

https://doi.org/10.1158/1535-7163.MCT-05-0192View

Published (Version of record) Open

Abstract

Neoplasm Transplantation

Cell Proliferation

Phosphatidylinositol 3-Kinases - antagonists & inhibitors

Dose-Response Relationship, Drug

Time Factors

DNA Fragmentation

Antineoplastic Agents - pharmacology

Chemotherapy, Adjuvant

Chromones - pharmacology

Ovarian Neoplasms - drug therapy

Cell Survival

Enzyme Inhibitors - pharmacology

Morpholines - pharmacology

Blotting, Western

Disease Progression

DNA - chemistry

Animals

Mice, Nude

Cell Line, Tumor

Carboplatin - pharmacology

In Vitro Techniques

Phosphorylation

Signal Transduction

Apoptosis

Signal transduction pathways associated with cancer progression and chemotherapeutic resistance are being investigated as molecular targets for chemotherapy. The phosphatidylinositol 3-kinase (PI3K) pathway has been found to be frequently amplified and have increased activity in ovarian cancer. The current study investigates the efficacy of an antagonist of PI3K, LY294002, in inhibiting ovarian cancer cell growth and survival both in vitro and in vivo. The hypothesis tested is that inhibition of PI3K signaling makes ovarian cancer cells susceptible to the effects of platinum-based chemotherapy. Observations show that LY294002 is an effective inhibitor of ovarian cancer cell growth and survival in vitro. Inhibition of PI3K/Akt signaling increased the sensitivity of ovarian cell cultures to the cytotoxic effects of carboplatin. The combined treatment of LY294002 and carboplatin was needed to optimally promote cellular apoptosis and decrease ovarian cancer cell survival in vitro. To extend these observations, a model involving in vivo i.p. growth of human ovarian tumors in a nude mouse was used. LY294002 in combination with carboplatin was more effective in inhibiting ovarian cancer cell xenograft growth than either agent alone. The results of this study suggest that the combined treatment of carboplatin and LY294002 can effectively decrease ovarian tumor progression and support the use of a PI3K inhibitor (e.g., LY294002) as an adjunct platinum-based drug therapy for treatment of ovarian cancer.

Metrics

10 Record Views

Details

Title: Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment
Creators: Suzanne D Westfall - Center for Reproductive Biology, School of Molecular Biosciences, Washington State University, Pullman, WA 99164-4231, USA
Michael K Skinner
Publication Details: Molecular cancer therapeutics, Vol.4(11), pp.1764-1771
Academic Unit: Biological Sciences, School of
Publisher: United States
Identifiers: 99900546795501842
Language: English
Resource Type: Journal article